Blockchain Registration Transaction Record

Oragenics to Present Concussion Drug ONP-002 at IPAC-RS 2026

Oragenics to present ONP-002, a first-in-class intranasal neurosteroid for concussion, at IPAC-RS 2026. Phase IIa trial enrolling; IND submission expected Q4 2026.

This news matters because concussion and mild traumatic brain injury affect millions worldwide, yet there are currently no FDA-approved pharmacological treatments. Oragenics’ ONP-002, with its innovative intranasal delivery, could become the first approved therapy, addressing a critical unmet need. The upcoming presentation and Phase IIa trial signal significant progress, offering hope to patients and potentially transformative value for investors. Moreover, the platform’s potential across other neurological conditions like Parkinson’s and Alzheimer’s highlights broader implications for brain health.